What You Should Know:
- LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
- The comprehensive package includes both the GLP-1 medication and access to LifeMD’s virtual weight management program. The initiative is part of LifeMD's collaboration with Novo Nordisk, announced last month, and leverages a recently completed integration with NovoCare® Pharmacy to offer
Read More
GLP-1
Vida Health Data Shows Obesity Success Beyond GLP-1 Medications
What You Should Know:
- Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity and related conditions, today announced outcomes from its Clinical Obesity Management Program, which demonstrate that most patients do not require expensive GLP-1s to achieve sustainable, significant weight loss.
- Data from more than 18,000 participants demonstrates that Vida’s tailored treatment plans and commitment to responsible prescribing deliver better outcomes,
Read More
PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Treatment
What You Should Know:
- PGxAI, a leader in AI-powered pharmacogenomics released a new report aimed at personalizing treatment regimens for patients taking semaglutide (commonly known by brand names Ozempic and Wegovy) and other widely used weight-management drugs.
- Utilizing advanced artificial intelligence models, the report analyzes patient-specific genetic data to identify and quantify genetic variants that impact drug efficacy and safety, finding that up to a third of
Read More
Wondr Health Launches GLP-1 Support For All Benefit Plans
What You Should Know:
- Wondr Health, a leader in digital, evidence-based lifestyle support and behavior-change interventions for weight and obesity management, has announced expansions to its comprehensive metabolic health programs.
- These expansions aim to help employers prevent and manage common and expensive weight-related chronic health conditions, while also mitigating the financial risks associated with GLP-1 coverage.
GLP-1 Support for all Benefit Plans
Wondr
Read More
Eli Lilly’s Oral GLP-1 Shows Positive Trial Results for Type 2 Diabetes
What You Should Know:
- Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone.
- Orforglipron stands out as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3
Read More
Phenomix Sciences Launches Clinical Trial to Predict GLP-1 Response Using Precision Obesity Test
What You Should Know:
- Phenomix Sciences (Phenomix), a commercial precision obesity medicine biotechnology company, today announced the initiation of its first prospective, placebo-controlled clinical study.
- The research will evaluate the MyPhenome™ test's ability to predict individual patient responses to semaglutide, a GLP-1-based therapy that has become a cornerstone in the treatment of obesity.
First Prospective Clinical Study of Semaglutide Using MyPhenome™
Read More
Virta Health Cuts GLP-1 Use for Weight Loss Over 50%, Driving Cost Savings for Payers
What You Should Know:
- Virta Health, a leader in diabetes reversal and sustainable weight loss through its nutrition-first methodology, has announced early results from its recently launched Sustainable Weight Loss GLP-1 prescribing capabilities.
- These outcomes signal a potentially transformative shift in obesity and weight loss management, offering organizations a responsible framework for covering GLP-1 medications while actively reducing reliance and controlling overall
Read More
Collective Health, Noom Health Offer Integrated GLP-1 Weight Management Solution
What You Should Know:
- Collective Health, a leader in employee health benefits, and Noom Health, the enterprise division of digital healthcare leader Noom announced a partnership to deliver Collective Health + Noom Med with SmartRx.
- The new program provides employers with an integrated weight management solution that includes a GLP-1 drug program, addressing the growing need for effective and affordable weight loss strategies.
Addressing the Obesity Epidemic
With
Read More
Affirm + FuturHealth Partner to Make GLP-1 Medications More Accessible with Flexible Payment Options
What You Should Know:
- FuturHealth, a provider of personalized weight-loss solutions partners with Affirm, the payment network that empowers consumers and helps merchants drive growth.
- The collaboration will enable FuturHealth customers to use Affirm's flexible, transparent pay-over-time options to purchase medications and wellness solutions.
Flexible, Transparent Way to Pay Over Time for GLP-1 Medications and Wellness Solutions
Now, FuturHealth customers who are
Read More
Quantum Health Launches New GLP-1 Solution for Employers
What You Should Know:
- Quantum Health, a provider of healthcare navigation and care coordination, has announced the expansion of its Premier Pharmacy platform to offer self-insured employers a new GLP-1 weight management solution.
- The GLP-1 offering, powered by Vida Health, aims to optimize prescribing patterns, improve clinical outcomes, and provide comprehensive member support for weight loss.
Growing Demand for GLP-1 Medications
The need for effective weight
Read More
